Optimized Procedure for Renaturation of Recombinant Human Bone Morphogenetic Protein-2 at High Protein Concentration

Biotechnology and Bioengineering

Volumn 85, Issue 6, 2004, Pages 601-609

  Vallejo, Luis Felipe ^a   Rinas, Ursula ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Bone morphogenetic protein 2; Escherichia coli; Renaturation

Indexed keywords

AMINO ACIDS; GENETIC ENGINEERING; PH EFFECTS; PROTEINS; REDOX REACTIONS;

GENE ENCODING;

BONE;

2 (CYCLOHEXYLAMINO)ETHANESULFONIC ACID; ARGININE; CYSTEINE; GLUTATHIONE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL INCLUSION; CODON; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DISULFIDE BOND; ESCHERICHIA COLI; FREEZING; GENE OVEREXPRESSION; IONIC STRENGTH; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; PH; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; PROTEIN RENATURATION; STORAGE; TEMPERATURE DEPENDENCE;

BONE MORPHOGENETIC PROTEINS; DIMERIZATION; ENZYME ACTIVATION; ENZYME STABILITY; ESCHERICHIA COLI; HUMANS; INCLUSION BODIES; OXIDATION-REDUCTION; PROTEIN FOLDING; PROTEIN RENATURATION; PROTONS; QUALITY CONTROL; RECOMBINANT PROTEINS; TAURINE; TEMPERATURE; TRANSFORMING GROWTH FACTOR BETA;

ESCHERICHIA COLI;

EID: 1442350517     PISSN: 00063592     EISSN: None     Source Type: Journal    
DOI: 10.1002/bit.10906     Document Type: Article

References (34)

1. Boden SD, Zdeblick TA, Sandhu HS, Heim SE. 2000. The use of rhBMP-2 in interbody fusion cages. Spine 25:376-381.
2. Bouxsein ML, Turek TJ, Blake CA, D'Augusta D, Li X, Stevens M, Seeherman HJ, Wozney JM. 2001. Recombinant human bone morphogenetic protein-2 accelerates healing in a rabbit ulnar osteotomy model. J Bone Joint Surg Am 83:1219-1230.
3. Buchner J, Pastan I, Brinkmann U. 1992. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem 205:263-270.
4. De Bernardez Clark E, Hevehan D, Szela S, Maachupalli-Reddy J. 1998. Oxidative renaturation of hen egg-white lysozyme. Folding vs aggregation. Biotechnol Prog 14:47-54.
5. De Bernardez Clark E, Schwarz E, Rudolph R. 1999. Inhibition of aggregation side reactions during in vitro protein folding. Methods Enzymol 309:217-236.
6. Fischer B, Perry B, Sumner I, Goodenough P. 1992. A novel sequential procedure to enhance the renaturation of recombinant protein from Escherichia coli inclusion bodies. Protein Eng 5:593-596.
7. Hevehan DL, De Bernardez Clark E. 1997. Oxidative renaturation of lysozyme at high concentrations. Biotechnol Bioeng 54:221-230.
8. Hogan BLM. 1996. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 10:1580-1594.
9. Honda J, Andou H, Mannen T, Sugimoto S. 2000. Direct refolding of recombinant human growth differentiation factor 5 for large-scale production process. J Biosci Bioeng 89:582-589.
10. Israel DI, Nove J, Kerns KM, Moutsatsos IK, Kaufman RJ. 1992. Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells. Growth Factors 7:139-150.
11. Kane JF. 1995. Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Curr Opin Biotechnol 6: 494-500.
12. Katoh S, Katoh Y. 2000. Continuous refolding of lysozyme with fed-batch addition of denatured protein solution. Process Biochem 35: 1119-1124.
13. Kirsch T, Nickel J, Sebald W. 2000. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J 19:3314-3324.
14. Kubler NR, Reuther JF, Faller G, Kirchner T, Ruppert R, Sebald W. 1998. Inductive properties of recombinant human BMP-2 produced in a bacterial expression system. Int J Oral Maxillofac Surg 27:305-309.
15. Li RH, Wozney JM. 2001. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol 19:255-265.
16. Maachupalli-Reddy J, Kelley BD, De Bernardez Clark E. 1997. Effect of inclusion body contaminants on the oxidative renaturation of hen egg white lysozyme. Biotechnol Prog 13:144-150.
17. McNulty DE, Huddleston MJ, Claffee B, Green S, Sathe G, Reeves R, Patel P, Kane JF. 2001. Translational problems associated with the rare arginine codon CGG in Escherichia coli. Frameshifting at CGG codons. In: Merten O-W, Mattanovich D, Lang C, Larsson G, Neubauer P, Porro D, Postma P, Teixeira de Mattos J, Cole JA, editors. Recombinant protein production with prokaryotic and eukaryotic cells. A comparative view on host physiology. Dordrecht: Kluwer. p 151-158.
18. Meyer RA, Gruber HE, Howard BA, Tabor OB, Murakami T, Kwiatkowski TC, Wozney JM, Hanley EN. 1999. Safety of recombinant human bone morphogenetic protein-2 after spinal laminectomy in the dog. Spine 24:747-754.
19. Müller C, Rinas U. 1999. Renaturation of heterodimeric platelet-derived growth factor from inclusion bodies of recombinant Escherichia coli using size-exclusion chromatography. J Chromatogr A 855:203-213.
20. Rattenholl A, Lilie H, Grossmann A, Stern A, Schwarz E, Rudolph R. 2001. The pro-sequence facilitates folding of human nerve growth factor from Escherichia coli inclusion bodies. Eur J Biochem 268:3296-3303.
21. Rudolph R, Böhm G, Lilie H, Jaenicke R. 1997. Folding proteins. In: Creighton TE, editor. Protein function. A practical approach. New York: IRL Press. p 57-99.
22. Ruppert R, Hoffmann E, Sebald W. 1996. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 237:295-302.
23. Scheufler C, Sebald W, Hülsmeyer M. 1999. Crystal structure of human bone morphogenetic protein-2 at 2.7. Å resolution. J Mol Biol 287: 103-115.
24. Sijwali PS, Brinen LS, Rosenthal PJ. 2001. Systematic optimization of expression and refolding of the Plasmodium falciparum cysteine protease Falcipain-2. Protein Expr Purif 22:128-134.
25. Suenaga M, Ohmae H, Tsuji S, Itoh T, Nishimura O. 1998. Renaturation of recombinant human neurotrophin-3 from inclusion bodies using an aggregation suppressor. Biotechnol Appl Biochem 28:119-124.
26. Terashima M, Suzuki K, Katoh S. 1996. Effective refolding of fully reduced lysozyme with a flow-type reactor. Process Biochem 31:341-345.
27. Tran-Moseman A, Schauer N, De Bernardez Clark E. 1999. Renaturation of Escherichia coli-derived recombinant human macrophage colony-stimulating factor. Protein Expr Purif 16:181-189.
28. Valentin-Opran A, Wozney J, Csimma C, Lilly L, Riedel GE. 2002. Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin Orthop 395:110-120.
29. Vallejo LF, Rinas U. 2002. Strategies for refolding inclusion body proteins. In: Villaverde A, editor. Protein production in bacterial cell factories. Trivandrum, India: Research Signpost. p 59-71.
30. Vallejo LF, Brokelmann M, Marten S, Trappe S, Cabrera-Crespo J, Hoffmann A, Gross G, Weich HA, Rinas U. 2002. Renaturation and purification of bone morphogenetic protein-2 produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli. J Biotechnol 94:185-194.
31. Vicik SM. 1999. Methods of refolding proteins by use of zwitterionic low molecular weight agents. Patent Application WO 99/18196.
32. Wang EA, Rosen V, D'Alessandro JS, Bauduy M, Cordes P, Harada T, Israel DI, Hewick RM, Kerns KM, LaPan P, Luxenberg DP, McQuaid D, Moutsatsos IK, Nove J, Wozney JM. 1990. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA 87:2220-2224.
33. Wetlaufer DB. 1962. Ultraviolet spectra of proteins and amino acids. Adv Prot Chem 17:303-390.
34. Winter J, Lilie H, Rudolph R. 2002. Renaturation of human proinsulin - a study on refolding and conversion to insulin. Anal Biochem 310: 148-155.